Yahoo
NasdaqCM - Delayed Quote USD

ImmuCell Corporation (ICCC)

10.26 -0.28 (-2.69%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for ICCC
  • Previous Close 10.54
  • Open 10.25
  • Bid 7.09 x 200
  • Ask 12.54 x 200
  • Day's Range 9.98 - 10.35
  • 52 Week Range 4.52 - 12.10
  • Volume 10,741
  • Avg. Volume 17,946
  • Market Cap (intraday) 93.183M
  • Beta (5Y Monthly) 0.57
  • PE Ratio (TTM) 146.57
  • EPS (TTM) 0.07
  • Earnings Date Nov 12, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est --
  • Motley Fool Rating Bearish

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.

immucell.com

73

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ICCC
66.83%
S&P 500 (^GSPC)
10.73%

1-Year Return

ICCC
68.47%
S&P 500 (^GSPC)
11.11%

3-Year Return

ICCC
108.11%
S&P 500 (^GSPC)
81.91%

5-Year Return

ICCC
16.59%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY20
Revenue 3.74M
Earnings 189k
Profit Margin 5.05%

Q1

FY20

Q2

FY20

Q3

FY20

Q4

FY20

0
2M
4M
-20.0%
-10.0%
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    2.57%

  • Return on Assets (ttm)

    6.25%

  • Return on Equity (ttm)

    2.57%

  • Revenue (ttm)

    30.68M

  • Net Income Avi to Common (ttm)

    787.37k

  • Diluted EPS (ttm)

    0.07

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.86M

  • Total Debt/Equity (mrq)

    39.67%

  • Levered Free Cash Flow (ttm)

    3.08M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: